{"groups":[{"description":"Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.","id":"FG000","title":"Ixazomib + Lenalidomide + Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"109"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"69"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"12"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"25"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"295"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"66"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"229"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 295 participants were enrolled and received the study treatment in this study.","recruitmentDetails":"Participant s took part in the survey at 101 investigative sites in Japan, from 2 April 2018 to 11 June 2021."}